Working… Menu

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02363491
Recruitment Status : Completed
First Posted : February 16, 2015
Last Update Posted : January 28, 2019
M.D. Anderson Cancer Center
Montefiore Medical Center
H. Lee Moffitt Cancer Center and Research Institute
New York Presbyterian Hospital
Information provided by (Responsible Party):
Opsona Therapeutics Ltd.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 2018
Actual Study Completion Date : December 2018
Certification/Extension First Submitted : January 24, 2019